in-PharmaTechnologist.com presents its latest round up of movements in the pharma sector, including appointments at Soligenx, Arno Therapeutics, Euthymics and Aeris Therapeutics.
Soligenx, a biopharmaceutical firm that develops drugs that treat side-effects of cancer medications, has appointed Jerome Zeldis, Celgene CEO, and Keith Brownlie, a former partner at Ernst & Young, to its Board of Directors.
Arno Therapeutics has named Alexander Zukiwski as its CMO. Zukiwski, who was previously VP of clinical research and CMO at MedImmune, will be responsible for the development of Arno’s pipeline of cancer treatments.
Thomas Shea has joined neuroscience-focused drugmaker Euthymics Bioscience as CFO. He has previously worked as CFO of Tolerx and Cubist Pharmaceuticals.
Euthymics has also appointed Anne Combebias as senior director of clinical research and drug safety pharmacovigilance and Thomas Wilson as director of quality and analytical.
Aeris Therapeutics has named Dennis D’Oria as VP of international sales and marketing and Charles Carter as CFO. D’Oria and Carter join Aeris from CooperVision and Intelligent Medical Devices, respectively.
Curaxis Pharmaceutical has made changes to its board of directors. Timothy Wright, former VP at Covidien, will become interim CEO and chairman joined by Terence Novak, Michael George, Michael Miller, Ivan Gothner and Stephen Leary. Current board members Bert Spilker and Judith Geaslen will continue to serve.
PharmacoFore has appointment of Joseph Stauffer as CMO and VP of corporate strategy and Narinder Banait as VP, Intellectual Property.
Oramed Pharmaceuticals has appointed Michael Berelowitz as chairman of its scientific advisory board. Prior to joining Oramed Berelowitz was SVP and head of clinical development and medical affairs at Pfizer’s specialty care unit.
Anthony Maida III has joined the board of directors of OncoSec Medical as chair of its audit committee. Before joining OncoSec Maida was chairman of BioConsul Drug Development.
Crescendo Biologics has named Matthew Roe as CBO. He joins the firm from Genzyme where he was senior director of business development and licensing.